ArticleBiomarker research2025
Liver-specific propanoate metabolism-derived 2-ethylhexanol as a novel biomarker for precise diagnosis and prognosis of hepatocellular carcinoma.
Article in Biomarker research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microbiome and metabolite signatures for cirrhosis to HCC risk stratification: progress, controversies, and gaps.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Alterations in propanoate metabolism are increasingly recognized as significant biomarkers for various liver disorders, notably hepatocellular carcinoma (HCC). To enhance diagnostic specificity for HCC, we conducted integrated binary omics and targeted metabolomics analyses, identifying liver-specific propanoate metabolism (LPM) gene signatures and associated metabolites. Leveraging data from 40 tissues and 81 cell subclasses, hepatocytes showed the highest metabolic specificity. Clinical validation using the TCGA-LIHC cohort highlighted LPM genes, notably ALDH2 and ABAT, as robust prognostic markers significantly associated with poor survival outcomes. Serum metabolomic profiling of 273 patients demonstrated that elevated toluene and xylene isomers and significantly reduced 2-ethylhexanol distinctly characterize HCC, distinguishing it from liver cirrhosis, hepatitis, and other cancers. These findings emphasize the potential of LPM-based metabolic profiling as a precise diagnostic and prognostic tool, with potential implications in targeted therapeutic development for HCC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.